^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    23h
    FRAPPE: Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Mayo Clinic | Trial completion date: Jul 2027 --> Jun 2028 | Trial primary completion date: Jul 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Keytruda (pembrolizumab)
    4d
    QPT-ORE-004: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, CanariaBio Inc. | Trial completion date: Jul 2025 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Zejula (niraparib) • OvaRex (oregovomab)
    4d
    National Cancer Institute "Cancer Moonshot Biobank" (clinicaltrials.gov)
    P=N/A, N=1600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    HR positive • MSI-H/dMMR
    5d
    Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Masonic Cancer Center, University of Minnesota | N=33 --> 3 | Trial primary completion date: Dec 2026 --> Mar 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    fludarabine IV
    5d
    BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Brown University | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    6d
    FLORA-4: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (clinicaltrials.gov)
    P3, N=615, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    6d
    QPT-ORE-006: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Jan 2026 --> Oct 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    6d
    Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (clinicaltrials.gov)
    P2, N=87, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    10d
    Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=111, Completed, University of Chicago | Active, not recruiting --> Completed
    Trial completion
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    metformin
    11d
    IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, University of Washington
    New P2 trial
    |
    carboplatin • EP-201
    11d
    A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (clinicaltrials.gov)
    P3, N=770, Recruiting, Merck Sharp & Dohme LLC | N=251 --> 770
    Enrollment change • Platinum sensitive
    |
    Avastin (bevacizumab) • dexamethasone • Jiataile (sacituzumab tirumotecan)
    13d
    Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (clinicaltrials.gov)
    P3, N=132, Recruiting, Ente Ospedaliero Ospedali Galliera | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AR (Androgen receptor)
    |
    carboplatin • paclitaxel • letrozole